Ness Ziona, Israel – 28 September 2010 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that the company's Chief Scientific Officer, Dr. Tamar Ben-Yedidia, will provide an overview of the Company's technology and clinical development progress at the World Vaccine Congress 2010:
World Vaccine Congress 2010
4 – 7 October 2010 in Lyon, France
Title: Delivering an epitope-based approach to universal influenza vaccine development
Dr. Tamar Ben-Yedidia has more than 16 years of experience in the field of immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd. (BTG), working on the development of a recombinant Hepatitis-B vaccine. She joined the Weizmann Institute of Science in 1994 and, under the auspices of Prof. Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens and focused on influenza. She continued this work when she left the Weizmann Institute in 2004 to join BiondVax as CSO. Dr. Ben-Yedidia received her Ph.D. from the Weizmann Institute after completion of her doctoral thesis entitled “A Peptide-Based Vaccine Against Influenza”. Dr. Ben Yedidia’s published research can be seen at: http://www.biondvax.com/
For further information, please contact:
Public Relations Consultant
Mob: +972-50-799 1121
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals (“the Company”), a publicly-traded company (TASE: BNDX) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine, the Multimeric-001 vaccine, with the potential to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains, such as Swine flu and Avian flu.
BiondVax’s proprietary technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.
BiondVax recently successfully concluded two Phase I/II trials in which the Multimeric-001 Universal Flu Vaccine was shown to be safe and immunogenic. The Company is now preparing for the first Phase II study, expected to commence in the second half of 2010.
For further information on BiondVax, please visit www.biondvax.com
# # #
BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDK) based in Rehovot, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine with the potential to provide protection against most human influenza virus strains.